超声内镜细针穿刺研究胰腺组织中微小核糖核酸的表达及临床意义

目的 研究超声内镜(EUS)-细针穿刺(FNA)胰腺组织中微小核糖核酸(miRNA)的表达及临床意义.方法 用实时定量逆转录-聚合酶链反应方法 检测23例胰腺癌和13例胰腺良性占位病变的EUS-FNA组织标本中miRNA-210、miRNA-21、miRNA-196a、miRNA-181a、miRNA-181b、miRNA-155和miRNA-16的表达并分析其临床意义.结果 胰腺癌中miRNA-210、miRNA-21、miRNA-196a、miRNA-181a、miRNA-181b的相对表达量分别为0.86±1.10、0.69±0.64、0.32±2.50、0.16±0.83、0.56±0.88,均较胰腺良性占位病变中(分别为-0.11±0.98、-0.03±0.97、-1.50±1.40、-0.53±1.10、-0.28±1.10)显著升高,P值分别=0.012、0.011、0.024、0.036、0.015.miRNA-16、miRNA-155在胰腺癌组织和胰腺良性占位病变中的相对表达量分别为-0.11±0.69、0.08±1.04和-0.73±1.26、-0.19±1.19,差异均无统计学意义(P值分别=0.067和0.467).miRNA-196a高表达与胰腺癌淋巴结转移和TNM分期正相关.结论 胰腺癌发生中存在多条miRNA异常高表达,其中miRNA-196a与胰腺癌临床恶性特征相关.

The expression of miRNAs in endoscopic ultrasound-guided fine needle pancreatic aspirates and its clinical significance

Objective To investigate the expression of miRNAs in endoscopic ultrasound (EUS)-guided fine needle pancreatic aspirates (FNA) and its clinical significance. Methods The expression of miRNA-210, miRNA-21, miRNA-196a, miRNA-181a, miRNA-181b, miRNA-155 and miRNA-16 in EUS-FNA specimen of 23 pancreatic cancer and 13 benign pancreatic masses was detected with quantitative real-time polymerase chain reaction (qRT-PCR) assays and its clinical significance was analyzed. Results The relatively expression quantity of miRNA-210, miRNA-21,miRNA-196a, miRNA-181a and miRNA-181b (0.86±1.10, 0.69±0.64, 0.32±2.50, 0.16±0.83and 0.56 ±0.88, respectively) was significant higher in pancreatic cancer than those in the benign pancreatic masses (-0.11±0.98,-0.03±0.97,-1.50±1.40,-0.53±1.10 and -0.28±1.10,respectively) (P value was 0. 012, 0. 011, 0. 024, 0. 036 and 0.015, respectively). The relatively expression quantity of miRNA-16 and miRNA-155 in pancreatic cancer and benign pancreatic masses was - 0.11 ± 0.69, 0.08 ± 1.04, - 0.73 ± 1.26 and - 0.19 ± 1.19 respectively, no statistic difference (P value was 0. 067 and 0. 467). The high expression of miRNA196a was positively correlated with pancreatic cancer lymphatic metastasis and clinical TNM staging. Conclusion There were multi miRNAs with abnormal high expression in the pancreatic cancer. Of those, miRNA-196a was associated with the clinical malignant features of pancreatic cancer.